Key Takeaways
Adagene Inc. (Nasdaq: ADAG) reported its antibody-based therapy, muzastotug, achieved a 29% overall response rate in a cohort of patients with a difficult-to-treat form of metastatic colorectal cancer, offering a potential new option where others have failed.
The data, released in the company’s full-year 2025 financial results, provides a critical update on the clinical progress of its lead drug candidate.
In detail, the 29% confirmed overall response rate was observed among 21 patients with microsatellite stable (MSS) colorectal cancer in the 20 mg/kg dose cohorts. A separate cohort at a 10 mg/kg dose showed a median overall survival of 19.4 months. The company highlighted the drug's tolerability, with a low 4% overall discontinuation rate and no Grade 4 or 5 treatment-related adverse events across 67 patients.
The positive data could be crucial for Adagene, a clinical-stage biotech that ended 2025 with $74.5 million in cash. With a stated cash runway into early 2028, the company is positioned to complete its randomized Phase 2 trial, with results expected in the first half of 2027.
Muzastotug is an antibody-based therapy, a type of treatment that uses the body's own immune system to fight cancer. Adagene is developing it for microsatellite stable colorectal cancer, a form of the disease that has historically shown limited response to immunotherapy treatments, representing a significant unmet medical need.
The ongoing Phase 2 trial is currently enrolling patients ahead of schedule. Adagene expects to provide further updates on the trial in 2026 and will begin a registration trial to seek regulatory approval once the optimal dose regimen has been established. The combination of promising efficacy and a favorable safety profile could make muzastotug a competitive candidate in the oncology market.
This article is for informational purposes only and does not constitute investment advice.
